VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Arteaga on PI3K Pathway Inhibitors

Carlos Arteaga
Published: Tuesday, Jan 06, 2015



Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

The PI3K pathway itself can be mutated at different levels and different genes that are involved in the pathway can be mutated and altered, says Arteaga. Several inhibitors are in clinical development that hit the pathway at multiple points.

Arteaga predicts that the use of these inhibitors could become a standard of care in the near future.



Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

The PI3K pathway itself can be mutated at different levels and different genes that are involved in the pathway can be mutated and altered, says Arteaga. Several inhibitors are in clinical development that hit the pathway at multiple points.

Arteaga predicts that the use of these inhibitors could become a standard of care in the near future.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x